The US Centre for Disease Control describes antibiotic resistance “as one of the world’s most pressing public health threats”.
Antimicrobial-resistant infections claim at least 50,000 lives each year across Europe and the US alone. The prevalence of antimicrobial resistance (AMR) has risen alarmingly over the last 40 years, and few truly novel antimicrobials have been developed. This has led to increased pressure on existing antibiotics and greater challenges in treating patients.
Inappropriate use of antimicrobials increases the risk to patients of colonisation and infection with resistant organisms. Reviewing the clinical diagnosis and de-escalating antibiotics at the earliest opportunity is considered highly desirable.
Momentum Bioscience is developing a range of innovative diagnostic products to help combat antibiotic resistance and sepsis by providing early detection of the presence and absence of bloodstream infections. Momentum’s ETGA® technology provides results up to 4 days earlier than current methods assisting clinicians with improved antibiotic stewardship, savings in pharmacy and other costs as well as active patient management and improved outcomes.